Leflunomide PCD Pharma Franchise Company

Cafoli Lifecare is a trusted Leflunomide PCD pharma franchise company offering 2 tablet formulations. Manufactured at WHO-GMP certified facilities, this range gives franchise partners a core disease-modifying antirheumatic drug (DMARD) for the chronic, long-term rheumatology segment.

What is Leflunomide?

Leflunomide is a disease-modifying antirheumatic drug (DMARD). Its active metabolite inhibits the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis, thereby suppressing the proliferation of activated lymphocytes that drive joint inflammation. This immunomodulatory action slows the underlying disease process rather than only relieving symptoms. Learn more on PubChem.

Therapeutic Applications of Leflunomide

Leflunomide is indicated for active rheumatoid arthritis and psoriatic arthritis, where it reduces joint inflammation, pain and structural damage. It is prescribed mainly by rheumatologists and, in some settings, by physicians managing chronic inflammatory arthritis.

Why Leflunomide is a High-Potential Molecule for Distributors

Rheumatoid and psoriatic arthritis require lifelong disease-modifying therapy, and leflunomide is a well-established, cost-effective DMARD frequently used alone or with methotrexate. Because patients remain on treatment for years under specialist supervision, it generates highly predictable, recurring demand, giving distributors a stable, loyalty-driven rheumatology molecule.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers exclusive district-wise monopoly rights, WHO-GMP certified and DCGI-approved formulations, attractive promotional inputs and marketing support, and the reliability of a network trusted by 1000+ franchise partners across India.

References

1. PubChem – Leflunomide Compound Summary, U.S. National Library of Medicine
2. PubMed – Clinical literature on Leflunomide